Estimation of pharmacokinetic parameters of alpha-lipoic acid in the chicks model


  • Marwa R. Abdulghani Department of Physiology, Biochemistry and Pharmacology, Faculty of Veterinary Medicine, University of Mosul, Mosul, Iraq
  • Ahmed S. Naser Department of Physiology, Biochemistry and Pharmacology, Faculty of Veterinary Medicine, University of Mosul, Mosul, Iraq



alpha-lipoic acid, broiler chicks, pharmacokinetic, UV spectrometric method


Background and objective: Alpha-lipoic acid is a drug used to treat diabetic neuropathy, and it has other uses as a dietary supplement. The target of the study was to investigate the concentration of therapeutic doses of Alpha-lipoic acid in the blood plasma of broiler chicks to define the pharmacokinetic parameters.

Methods: A randomized controlled study was performed on thirty-five healthy broiler chicks of seven days old, chicks were injected into the peritoneum with a single dose of analgesic ED50 80mg /kg b.wt, following injection of the drug, blood samples were collected at 0.25, 0.5, 1, 2, 4, 24 h (five chicks per time) from the jugular vein. Then the  blood plasma was obtained, the concentrations of Alpha-lipoic acid  in blood  plasma samples were determined utilizing UV Spectrometric Method, the pharmacokinetic parameters were determined by the PKSolver program. Time versus concentration curve for Alpha-lipoic acid was obtained from the program. The pharmacokinetic parameters were determined with non-compartmental models.

Results: The concentration of Alpha-lipoic acid  in the blood plasma of chicks injected with Alpha lipoic at a dose (80 mg/kg) were 134.6±7.17, 178.5±4.10 ,192.4±7.83  ,158.5±11.05  ,147.1±10.16, 122.8±7.09  µg/ml at times   0.25, 0.5, 1, 2, 4, and 24 hours respectively. The maximum plasma concentration was 192.4µg/ml during a period of 1 hour of injection. The terminal elimination half-life was 65hours, the terminal phase elimination rate constant was 0.011 h-1 , the mean residence time was 94h, and the area under the curve from time 0 to infinity was 14960 µg.h/ml.

Conclusions:  Our study concluded that the peak of the analgesic effect of alpha lipoic acid was one hour after treatment; furthermore, it is characterized by a long elimination half-life and a poor clearance from the chick’s body, which is reflected in the long effects of its pharmacological properties


Download data is not yet available.


Abdelhalim, M. A. K. et al. (2020) ‘The protective roles of vitamin E and α-lipoic acid against nephrotoxicity, lipid peroxidation, and inflammatory damage induced by gold nanoparticles’, International journal of nanomedicine, 15, p. 729. DOI:

Alatrushi, A. N. and Naser, A. S. (2021) ‘The Safety Profile of the Anesthetic Effect of Alfaxalone and Its Interaction with Xylazine and Ketamine in Chick’s Model ()’, Macedonian Veterinary Review. DOI:

Amenta, F. et al. (2008) ‘Pharmacokinetics of different formulations of tioctic (alpha-lipoic) acid in healthy volunteers’, Clinical and Experimental Hypertension, 30(8), pp. 767–775. DOI:

Banik, S. et al. (2021) ‘Self‐emulsifying drug delivery system of (R)‐α‐lipoic acid to improve its stability and oral absorption’, Biopharmaceutics & Drug Disposition, 42(5), pp. 226–233. DOI:

Bernkop‐Schnürch, A. et al. (2004) ‘Development of a sustained release dosage form for α‐lipoic acid. I. Design and in vitro evaluation’, Drug development and industrial pharmacy, 30(1), pp. 27–34. DOI:

Biewenga, G. P., Haenen, G. R. M. M. and Bast, A. (1997) ‘The pharmacology of the antioxidant lipoic acid’, General Pharmacology: The Vascular System, 29(3), pp. 315–331. DOI:

Brufani, M. (2014) ‘Acido α-lipoico farmaco o integratore. Una panoramica sulla farmacocinetica, le formulazioni disponibili e le evidenze cliniche nelle complicanze del diabete’, Prog. Nutr, 16, pp. 62–74.

Bustamante, J. et al. (1998) ‘α-Lipoic acid in liver metabolism and disease’, Free radical biology and medicine, 24(6), pp. 1023–1039. DOI:

Carlson, D. A. et al. (2007) ‘The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects’, Alternative Medicine Review, 12(4), p. 343.

Cronan, J. E., Fearnley, I. M. and Walker, J. E. (2005) ‘Mammalian mitochondria contain a soluble acyl carrier protein’, FEBS letters, 579(21), pp. 4892–4896. DOI:

Dixon, W. J. (1980) ‘Efficient analysis of experimental observations’, Annual review of pharmacology and toxicology, 20(1), pp. 441–462. DOI:

Evrard, H. C. and Balthazart, J. (2002) ‘The assessment of nociceptive and non-nociceptive skin sensitivity in the Japanese quail (Coturnix japonica)’, Journal of neuroscience methods, 116(2), pp. 135–146. DOI:

Gomes, M. B. and Negrato, C. A. (2014) ‘Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases’, Diabetology & metabolic syndrome, 6(1), pp. 1–18. DOI:

Hu, J. et al. (2017) ‘Alpha-lipoic Acid suppresses P2X receptor activities and visceral hypersensitivity to colorectal distention in diabetic rats’, Scientific reports, 7(1), pp. 1–9. DOI:

Joksimovic, S. L. et al. (2018) ‘Selective inhibition of CaV3. 2 channels reverses hyperexcitability of peripheral nociceptors and alleviates postsurgical pain’, Science signaling, 11(545). DOI:

Kang, K. P. et al. (2009) ‘Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation’, Nephrology Dialysis Transplantation, 24(10), pp. 3012–3020. DOI:

Lee, W. Y. et al. (2009) ‘Molecular mechanisms of lipoic acid modulation of T-type calcium channels in pain pathway’, Journal of Neuroscience, 29(30), pp. 9500–9509. DOI:

Murali, P. and Sherin, G. K. (2020) ‘Supplementation of alpha lipoic acid on serum biochemical, minerals and antioxidant status in broiler chicken fed diet with animal fat’, J. Entomol. Zool. Stud, 8, pp. 1622–1626.

Naser, A. S. and Albadrany, Y. M. (no date) ‘The neurobehavioral effects of flumazenil in chicks’, group, 25, p. 27.

Patni, M. and Rawat, S. (no date) ‘Novel Analytical Method Development and Validation for Simultaneous Estimation of Metformin Alpha Lipoic Acid in Bulk and Pharmaceutical Dosage Form by UV Spectrometric Method’.

Perera, J. et al. (2011) ‘Neuroprotective effects of alpha lipoic acid on haloperidol-induced oxidative stress in the rat brain’, Cell & bioscience, 1(1), pp. 1–6. DOI:

Pop, A. L. et al. (2021) ‘Evaluation of Dissolution Profiles of a Newly Developed Solid Oral Immediate-Release Formula Containing Alpha-Lipoic Acid’, Processes, 9(1), p. 176. DOI:

Singh, U. and Jialal, I. (2008) ‘Retracted: alpha-lipoic acid supplementation and diabetes’, Nutrition reviews, 66(11), pp. 646–657. DOI:

Uchida, R. et al. (2015) ‘Enantioselective pharmacokinetics of α-lipoic acid in rats’, International journal of molecular sciences, 16(9), pp. 22781–22794. DOI:

Wollin, S. D. and Jones, P. J. H. (2003) ‘α-Lipoic acid and cardiovascular disease’, The Journal of nutrition, 133(11), pp. 3327–3330. DOI:

Yadav, V. et al. (2010) ‘Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters’, Multiple Sclerosis Journal, 16(4), pp. 387–397. DOI:

Graphical abstrat-91-2021



How to Cite

Abdulghani, M., & Naser, A. (2022). Estimation of pharmacokinetic parameters of alpha-lipoic acid in the chicks model. Baghdad Journal of Biochemistry and Applied Biological Sciences, 3(02), 122–132.